States Are Banning Today's Molecule. The Chemistry Is Already Moving Past It.

Legislators can ban today's molecule. That does not make the chemistry disappear.

States are increasingly writing kratom laws around compounds they already know by name: 7-hydroxymitragynine, mitragynine pseudoindoxyl and selected derivatives. A 2023 U.S. patent shows why that strategy can become a race against chemistry. The principal kratom alkaloid, mitragynine, is not merely a constituent of the plant. It is a chemical scaffold that researchers have repeatedly modified into related compounds.

U.S. Patent 11,760,758, titled Mitragynine Analogs for the Treatment of Pain, Mood Disorders and Substance Use Disorders, describes extensive chemistry built around mitragynine and related structures. The patent's numbered compounds and intermediates extend through Compound 70, with multiple families of substituted mitragynine, 7-OH and pseudoindoxyl-related structures.

That does not mean 70 new kratom opioids are currently being sold. Some numbered substances are intermediates or protected forms. The warning is more precise: once the mitragynine scaffold is available, the patent demonstrates a broad field of additional chemistry. A statute that names only today's compounds has to confront what happens when tomorrow's compound has a different name.

The issue in 30 seconds

What lawmakers need to know

Start with what the plant already makes

Kratom leaf contains mitragynine. That matters because a chemist does not necessarily have to construct mitragynine's complex molecular framework from basic chemicals before modifying it. The patent discusses mitragynine obtained from commercial kratom material and then uses the existing molecule as the foundation for further chemistry.

This is the distinction between a botanical source and a finished chemical. A downstream analog need not occur naturally in meaningful quantities for natural kratom to remain relevant to its manufacture. The plant can supply an upstream molecular starting point even when later chemical transformations produce a different substance.

The patent maps a chemical family, not a single pathway

The document repeatedly modifies different positions on the mitragynine framework. Its schemes include C11, C12 and other substitutions and extend related chemistry across mitragynine, 7-hydroxymitragynine and pseudoindoxyl-type structures.

One particularly clear portion of the patent describes parallel series across these related scaffolds. Elsewhere, additional substitutions and intermediates expand the number of structures still further. The important policy point is not the raw compound count. It is that the chemistry branches.

A statute that names only today's best-known molecules may therefore address those named molecules without necessarily addressing every future substance that can be produced by modifying the same underlying scaffold.

These structural changes can change opioid pharmacology

The patent is not merely a catalog of decorative chemical structures. It evaluates selected compounds at the mu-, delta- and kappa-opioid receptors and reports that structural changes can alter receptor potency, efficacy and selectivity.

That is why the distinction matters for public policy. Two molecules can share the mitragynine backbone while having meaningfully different pharmacology. Conversely, a law written around the concentration of one named alkaloid may say little about another modified molecule unless the statute captures it independently.

Seventy numbers do not mean seventy retail drugs

Precision is important. The patent numbers compounds and synthetic intermediates through 70. Some are final characterized analogs; others are intermediates used to reach later compounds. It would therefore be inaccurate to report that the patent proves “70 kratom opioids are on the market.” It does not.

What can be stated from the document is narrower and stronger: researchers demonstrated extensive, position-by-position modification of the mitragynine family and experimentally characterized numerous resulting compounds.

That is enough to expose the weakness of treating the known kratom-related chemical universe as a list containing only mitragynine, 7-OH and pseudoindoxyl.

This is laboratory chemistry, not a kitchen recipe

The transformations in the patent require real synthetic chemistry. The experimental section uses controlled reactions, specialized reagents and catalysts, purification, and analytical characterization. Nothing in the patent supports the claim that a consumer can casually turn a bag of kratom powder into these analogs at home.

But that distinction should not be confused with impossibility. A chemical laboratory does not have to sit inside a university or pharmaceutical company. The relevant regulatory question is whether commercial or illicit manufacturers can obtain an upstream alkaloid and perform downstream chemistry, not whether the retail customer can perform it personally.

This page intentionally does not reproduce reaction conditions, quantities, reagent combinations or step-by-step synthesis instructions.

The problem with a simple “natural versus synthetic” line

A molecule extracted from a plant can subsequently be chemically modified. Those two facts are not contradictory. The starting material can be botanical while the finished compound is semi-synthetic or synthetic in the ordinary chemical sense.

That creates an enforcement problem for statutes that rely heavily on words such as “natural,” “synthetic,” “derived,” “isolated,” “concentrated” or “converted.” The finished product does not reveal its manufacturing history by appearance. Determining what is present generally requires chemical analysis; determining how it was made can be a still more difficult question.

The issue is therefore not solved simply by preserving “natural kratom” while prohibiting a short list of altered compounds. The statutory language has to specify what material and what transformations it actually covers.

A precedent lawmakers already know

Synthetic cathinones showed what happens when laws chase names

Synthetic cathinones provide a cleaner regulatory comparison. As particular compounds were controlled, chemically related new psychoactive substances continued to appear. Federal law eventually had to address not only specifically named substances, but also substances that qualify as controlled substance analogues when the statutory requirements are met.

This is not a claim that mitragynine analogs are chemically the same as synthetic cathinones. They are not. The comparison is regulatory: when a market can move among related molecules, compound-by-compound legislation risks becoming a game of catch-up.

What the patent proves, and what it does not

It does show: mitragynine can serve as a starting scaffold for extensive chemical modification; numerous related compounds can be synthesized and characterized; and selected analogs have measurable opioid-receptor pharmacology.

It does not show: that every patented analog is commercially manufactured, that every kratom company uses these routes, or that consumers can perform these transformations without laboratory chemistry.

Those limits matter. They also leave the central policy problem intact: a regulatory scheme focused only on compounds already known by name may not capture the full range of chemistry that can be built around a legally available upstream scaffold.

Read the source documents

1. U.S. Patent No. 11,760,758 B2. Mitragynine Analogs for the Treatment of Pain, Mood Disorders and Substance Use Disorders. Issued September 19, 2023. Local copy of the full patent.
2. U.S. Drug Enforcement Administration. Federal materials on synthetic cathinones and new psychoactive substances document the continuing emergence of chemically related compounds.
3. Controlled Substance Analogue Enforcement Act. 21 U.S.C. §§ 802(32), 813. Federal law provides a mechanism for certain substantially similar substances intended for human consumption to be treated as Schedule I controlled substances when the statutory elements are satisfied.
4. Global Kratom Policy Review. Where Do High-Potency Kratom Products Come From? Companion review tracing the documented relationship among kratom leaf, mitragynine, 7-OH, pseudoindoxyl and commercial products.

Patent disclosures establish that described chemistry was disclosed and, where experimental examples are provided, performed by the inventors. A patent does not establish that every described compound is commercially manufactured or sold.